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QUESTION WHY IT MATTERS
Researchers are looking beyond BRCA for other gene mutations that could help to set breast cancer in motion. The genetic links probably will not be as strong, but finding them could still prove lifesaving.
Some women are more likely to develop breast cancer because they carry a mutation in a BRCA gene (see S116), but even the risk for these women is shaped by exposure to hormones, which in turn are influenced by exercise, weight control and pregnancy.
Knowing which women are susceptible to breast cancer -and why -could illuminate the root causes of the disease and lead to new approaches for prevention and treatment.
What are the risk factors for the disease?
Each case of cancer is different, and so is each immune system. Matching the right treatment with the right patient could prove to be the defining challenge of the future.
With more than 40 clinical trials underway, data continues to roll in (see page S105). So far, immunotherapy, including anti-cancer vaccines, alone or in combination with other therapies, seems to be especially promising for cases of 'triple-negative' breast cancer.
Harnessing the immune system to fight breast cancer could be a winning strategy, a major disappointment or both. For certain women, immunotherapy could mean not just a treatment, but also a cure.
What are the possibilities, and limits, of immunotherapy?
Researchers are sorting through genetic and molecular biomarkers that could help to forecast the course of an individual tumour. Such predictions may never be 100% accurate, but a little more clarity could go a long way.
Roughly 15-30% of tumours detected by screening are unlikely to cause trouble if left alone. Ductal carcinoma in situ, -a common cancer of the milk ducts -rarely turns invasive, but women with the disease often undergo surgery (see page S114).
Treatment for breast cancer can be disfiguring, expensive and painful. Identifying the tumours that actually pose a threat can focus therapy where it is needed, while saving millions of women from potentially harmful interventions.
Which cancers need to be treated?
Radiologists are working to improve the accuracy and clarity of breast imaging, and public health experts are developing evidence-based guidelines that can save lives while minimizing harm.
Mammograms prevent about 4 cancer deaths for every 1,000 women screened regularly for 20 years. The benefits seem to be especially small for women in their 40s (see page S118).
Women face a cacophony of conflicting recommendations regarding screening. Should they be screened every year starting at age 40, every 2 years at age 50 or never? Although overscreening can create false alarms, under-screening could lead to preventable deaths.
